Nutraceutical compositions and methods of their use in treating Caliciviridae family viruses are provided. The viruses can be norovirus or sapovirus. An exemplary nutraceutical composition includes Fagopyrum dibotyo extract. Another nutraceutical composition for treating viral gastroenteritis includes 5, 7, 3′, 4′-tetrahydroxyflavan-3-ol C.sub.4-C.sub.8 dimers, quercetin, rutin, or a combination thereof. The nutraceutical compositions inhibit or reduce entry of Caliciviridae family viruses into intestinal epithelial cells of the subject.

The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABA.sub.A receptors, such as preferential modulation of α4β3δ GABA.sub.A receptors over α1β2γ2 GABA.sub.A receptors. The invention also provides methods of treating GABA.sub.A disorders using such compositions.

The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABA.sub.A receptors, such as preferential modulation of α4β3δ GABA.sub.A receptors over α1β2γ2 GABA.sub.A receptors. The invention also provides methods of treating GABA.sub.A disorders using such compositions.

The present disclosure is directed to methods of improving the therapeutic effectiveness and safety profile of ibogaine for the treatment of conditions including, but not limited to, alcoholism, substance abuse disorder, and opioid use disorder.

The present disclosure is directed to methods of improving the therapeutic effectiveness and safety profile of ibogaine for the treatment of conditions including, but not limited to, alcoholism, substance abuse disorder, and opioid use disorder.

The invention relates to ciclesonide or a pharmaceutically acceptable salt thereof or a composition comprising ciclesonide or a pharmaceutically acceptable salt thereof for the use in a method of ameliorating quality of life (QOL) in equines, preferably horses.

The invention relates to ciclesonide or a pharmaceutically acceptable salt thereof or a composition comprising ciclesonide or a pharmaceutically acceptable salt thereof for the use in a method of ameliorating quality of life (QOL) in equines, preferably horses.

The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.

The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.

Disclosed here in are methods and kits for identifying a prostate cancer treatment for a subject. The methods include obtaining a fluid sample from the subject, the fluid sample comprising noncellular DNA (ncDNA) from the subject, transforming the ncDNA into a plurality of genomic variations to determine if the ncDNA contains castration-resistant structural variations including at least one of a genomic alteration in AR encoding an androgen receptor and a genomic alteration of an AR enhancer; and identifying the prostate cancer treatment for the subject based on the plurality of genomic variations.